Interatrial Shunt Helps Decompress Failing Heart
By HospiMedica International staff writers Posted on 24 Oct 2019 |
Image: The Corvia InterAtrial Shunt Device (IASD) (Photo courtesy of Corvia Medical).
A novel implantable cardiac shunt helps treat heart failure (HF) patients with preserved and mid-range ejection fraction.
The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implantable device designed to help diastolic HF function by forming a channel that connects left and right atria, thus facilitating continuous and dynamic decompression of the left atrium and enabling it to relax at rest and physical activity. Once in place, a permanent passage is created in the septum between the atria, resulting in reduction in HF symptoms, improved quality of life, and reduced hospitalization rates.
The IASD, which has been granted “Breakthrough Device” designation by the U.S. Food and Drug Administration (FDA), is being studied in the REDUCE LAP-HF II study, a large multi-national prospective, double-blind, sham-controlled trial randomizing 608 HFpEF and HFmrEF patients in the United States, European Union, Australia, Japan, and Canada. One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers, demonstrated shunt patency for all participants who received the implant.
“Receiving Breakthrough Device designation from the FDA underscores the significant unmet need for more effective treatment options for heart failure patients,” said George Fazio, President and CEO of Corvia Medical. “We look forward to continuing our work with the FDA through our ongoing pivotal trial in more than 100 hospitals, and providing the clinical evidence which will accelerate the timeline to bring the IASD to the U.S. market.”
There are two types of HF; HF with reduced ejection fraction (HFrEF, systolic heart failure), and heart failure with preserved or mid‐range ejection fraction (HFpEF/HFmrEF), previously called diastolic heart failure. HFpEF accounts for approximately 50% of all HF, but treatment options are limited, consisting mainly of diuretics and fluid balance control. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.
Related Links:
Corvia Medical
The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implantable device designed to help diastolic HF function by forming a channel that connects left and right atria, thus facilitating continuous and dynamic decompression of the left atrium and enabling it to relax at rest and physical activity. Once in place, a permanent passage is created in the septum between the atria, resulting in reduction in HF symptoms, improved quality of life, and reduced hospitalization rates.
The IASD, which has been granted “Breakthrough Device” designation by the U.S. Food and Drug Administration (FDA), is being studied in the REDUCE LAP-HF II study, a large multi-national prospective, double-blind, sham-controlled trial randomizing 608 HFpEF and HFmrEF patients in the United States, European Union, Australia, Japan, and Canada. One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers, demonstrated shunt patency for all participants who received the implant.
“Receiving Breakthrough Device designation from the FDA underscores the significant unmet need for more effective treatment options for heart failure patients,” said George Fazio, President and CEO of Corvia Medical. “We look forward to continuing our work with the FDA through our ongoing pivotal trial in more than 100 hospitals, and providing the clinical evidence which will accelerate the timeline to bring the IASD to the U.S. market.”
There are two types of HF; HF with reduced ejection fraction (HFrEF, systolic heart failure), and heart failure with preserved or mid‐range ejection fraction (HFpEF/HFmrEF), previously called diastolic heart failure. HFpEF accounts for approximately 50% of all HF, but treatment options are limited, consisting mainly of diuretics and fluid balance control. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.
Related Links:
Corvia Medical
Latest Critical Care News
- Portable System for Warming Blood and IV-Fluids Reduces Hypothermia Risk in Hemorrhaging Patients
- AI-Generated Real-Time Alerts for Declining Health Speeds Up Treatment and Reduces Hospital Deaths
- Breakthrough Computational Method Predicts Sudden Cardiac Death
- Ingestible Microbiome Sampling Pill to Help Diagnose Wide Range of Health Conditions
- GPS-Like Smart Pills with AI Provide Real-Time 3D Monitoring Of Gastrointestinal Health
- Bioengineering Breakthrough to Improve Bone Regeneration Treatments
- Soft Robots with Electronic Skins and Artificial Muscles to Provide Medical Treatment
- AI Camera Technology Helps Doctors Quickly Assess Severity of Infections
- Machine Learning Delivers Personalized Oxygenation for Patients on Ventilators
- New AI Algorithm Detects Rare Epileptic Seizures from EEG Data
- Facial Thermal Imaging Combined with AI Predicts Coronary Artery Disease
- AI Technology Predicts Cardiac Events 10 Years in Advance
- Recyclable ‘Smart Skin’ Monitors Biological Signals on Demand
- Novel Catheter to Reduce Risk for Associated Urinary Tract Infections and Sepsis
- AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients
- Flexible Device Enables Sweat Gland Stimulation and Simultaneous Biosensing